# Appendix C: License Value Estimation Model

---

## C.1 License Structure Overview

### C.1.1 Typical Biotech Licensing Structure

```
Total license value = Upfront + Milestones + Royalties

├── Upfront (signing fee)
│   └── One-time payment at signing, typically 10-20% of total
│
├── Milestones
│   ├── Clinical milestones (Phase 3 start, data release)
│   ├── Regulatory milestones (FDA acceptance, approval)
│   └── Commercial milestones (Peak Sales targets)
│
└── Royalties
    └── Post-launch payments based on net sales, typically 10-15%
```

### C.1.2 Component Proportions by Stage

| Component | Proportion of Total | Description |
|-----------|--------------------|-|
| Upfront | 10-20% | Highest certainty at signing |
| Clinical milestones | 20-30% | Depends on trial success |
| Regulatory milestones | 15-25% | Depends on approval |
| Commercial milestones | 20-30% | Depends on commercial success |

---

## C.2 LT3001 License Value Estimation

### C.2.1 Base Case Scenario

| Item | Amount (USD) | Share | Description |
|------|--------------|-------|-------------|
| **Upfront** | **$70 million** | 14% | Paid at signing |
| Option Fee | $40 million | 8% | Paid 2027 Q4 |
| Clinical milestones | $400 million | 26% | Phase 3 start, data release |
| Regulatory milestones | $250 million | 16% | FDA acceptance, approval |
| Commercial milestones | $550 million | 36% | Peak Sales targets |
| **Total** | **$1.55 billion** | 100% | — |

### C.2.2 Scenario Analysis

| Scenario | Upfront | Milestones | Total | Probability |
|----------|---------|------------|-------|-------------|
| Conservative | $40M | $800M | **$1.2B** | 25% |
| **Base Case** | **$70M** | **$1.08B** | **$1.55B** | 50% |
| Optimistic | $100M | $1.5B | **$2.1B** | 25% |
| **Weighted Average** | — | — | **$1.59B** | — |

---

## C.3 Milestone Detailed Breakdown

### C.3.1 Clinical Milestones

| Milestone | Amount | Expected Timing | Achievement Probability |
|-----------|--------|-----------------|------------------------|
| China Phase 3 start | $20 million | 2026 Q1 | 95% |
| Global Phase 3 start | $30 million | 2027 Q1-Q2 | 85% |
| China Phase 3 data release | $100 million | 2029 Q2-Q3 | 40% |
| Global Phase 3 data release | $150 million | 2029 Q4-2030 Q1 | 40% |
| **Clinical Milestones Total** | **$400 million** | — | — |

### C.3.2 Regulatory Milestones

| Milestone | Amount | Expected Timing | Achievement Probability |
|-----------|--------|-----------------|------------------------|
| NMPA acceptance | $20 million | 2029 Q4 | 40% |
| FDA acceptance | $30 million | 2030 Q1-Q2 | 35% |
| China approval | $50 million | 2030 Q2-Q3 | 35% |
| FDA approval | $150 million | 2030 Q3-2031 Q1 | 30% |
| **Regulatory Milestones Total** | **$250 million** | — | — |

### C.3.3 Commercial Milestones

| Milestone | Amount | Condition | Achievement Probability |
|-----------|--------|-----------|------------------------|
| First commercial sale | $50 million | Post-launch | 30% |
| Annual sales $500M | $100 million | On path to Peak | 25% |
| Annual sales $1B | $150 million | On path to Peak | 20% |
| Annual sales $2B | $250 million | At Peak | 15% |
| **Commercial Milestones Total** | **$550 million** | — | — |

---

## C.4 Royalty Estimation

### C.4.1 Royalty Rate Assumptions

| Sales Tier | Royalty Rate | Description |
|------------|--------------|-------------|
| $0-500M | 10% | Initial stage |
| $500M-1.5B | 12% | Medium sales |
| $1.5B+ | 15% | High sales bonus |
| **Weighted Average** | **~12%** | — |

### C.4.2 Royalty Income Projections

| Year | Global Sales (Est.) | Royalty Rate | **Lumosa Royalty** |
|------|---------------------|--------------|-------------------|
| 2032 | $800M | 10% | $80M |
| 2033 | $1.8B | 12% | $220M |
| 2034 | $3.2B | 12% | $380M |
| 2035 | $4.5B | 12% | $540M |
| **2036 (Peak)** | **$5.3B** | **12%** | **$640M** |

---

## C.5 Comparable Transaction Reference

### C.5.1 Recent Neurology Licensing Cases

| Transaction | Year | Stage | Upfront | Total | Royalty |
|-------------|------|-------|---------|-------|---------|
| Biogen/Sage (Depression) | 2020 | Phase 3 | $875M | $2.2B | 15% |
| BMS/Karuna (Schizophrenia) | 2023 | Phase 3 | $14.0B | Full acquisition | — |
| Roche/Prothena (Alzheimer's) | 2023 | Phase 2 | $200M | $2.75B | — |
| **Median** | — | — | **~$200-300M** | **~$2.0-2.5B** | **12-15%** |

### C.5.2 Historical Stroke Drug Transactions

| Transaction | Year | Description | Implication |
|-------------|------|-------------|-------------|
| Genentech/Activase | 1996 | tPA monopoly for 30 years | Massive first-mover advantage |
| No major licensing | 1996-2024 | All failures | Market awaiting new breakthrough |

**Conclusion**: No recent comparable stroke transactions, but massive unmet need supports higher license value.

---

## C.6 Sensitivity Analysis

### C.6.1 Upfront Sensitivity

| Upfront | NTD (Billion) | Stock Price Impact |
|---------|---------------|-------------------|
| $40M | 1.28 | Below expectations, short-term negative |
| **$70M** | **2.24** | **Meets expectations** |
| $100M | 3.2 | Beats expectations, short-term positive |

### C.6.2 Total Deal Value Sensitivity

| Total Value | Risk-Adjusted Value | Valuation Impact |
|-------------|--------------------|-|
| $1.2B | $480M (40%) | Valuation down 15-20% |
| **$1.55B** | **$620M (40%)** | **Base case** |
| $2.1B | $840M (40%) | Valuation up 20-30% |

### C.6.3 Royalty Rate Sensitivity

| Royalty Rate | Peak Annual Royalty | Long-term Valuation Impact |
|--------------|--------------------|-|
| 10% | $530M | Valuation down 15% |
| **12%** | **$640M** | **Base case** |
| 15% | $790M | Valuation up 20% |

---

## C.7 Cash Flow Timeline

### C.7.1 License Payment Cash Flows

| Year | Event | Cash Inflow | Cumulative |
|------|-------|-------------|------------|
| 2026 | Upfront | $70M | $70M |
| 2027 | Option Fee + Milestone | $70M | $140M |
| 2028 | Clinical milestone | $50M | $190M |
| 2029 | Clinical + Regulatory milestones | $200M | $390M |
| 2030 | Regulatory milestone | $200M | $590M |
| 2031 | Launch milestone | $50M | $640M |
| **Cumulative Milestones** | — | **$640M** | — |

### C.7.2 Royalty Cash Flows

| Year | Annual Royalty | Cumulative Royalty | Cumulative Total Income |
|------|----------------|-------------------|------------------------|
| 2032 | $80M | $80M | $720M |
| 2033 | $220M | $300M | $940M |
| 2034 | $380M | $680M | $1.32B |
| 2035 | $540M | $1.22B | $1.86B |
| 2036 | $640M | $1.86B | $2.50B |

---

## C.8 Conclusion

| Item | Estimate |
|------|----------|
| **Upfront** | **$50-100 million** |
| **Total license value** | **$1.2-2.1 billion** |
| **Royalty rate** | **10-15%** |
| **Peak annual royalty** | **$500-800 million** |
| **Signing timeline** | **2026 Q4** |

---

**[Previous Appendix: Appendix B — Competitor Comparison Matrix](-Appendix_B_Competitor_Matrix.md)** | **[Next Appendix: Appendix D — Reference Materials](-Appendix_D_References.md)**

---

*Based on comparable transactions and industry conventions; actual results may differ significantly*
